Virtu Financial LLC Raises Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Virtu Financial LLC lifted its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 265.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 150,911 shares of the company’s stock after purchasing an additional 109,666 shares during the period. Virtu Financial LLC owned about 0.07% of Hims & Hers Health worth $3,047,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Arizona State Retirement System grew its stake in Hims & Hers Health by 3.0% in the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock worth $815,000 after acquiring an additional 1,173 shares in the last quarter. Belpointe Asset Management LLC boosted its holdings in shares of Hims & Hers Health by 10.0% in the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after purchasing an additional 1,205 shares during the period. Victory Capital Management Inc. grew its stake in Hims & Hers Health by 6.6% in the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after purchasing an additional 1,212 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Finally, Swiss National Bank raised its position in Hims & Hers Health by 0.7% during the 1st quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after purchasing an additional 2,000 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on HIMS. Truist Financial raised their price target on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Piper Sandler reissued a “neutral” rating and set a $18.00 target price on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Citigroup lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $16.00 to $20.00 in a report on Wednesday, May 22nd. Finally, Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price for the company. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Hims & Hers Health has an average rating of “Moderate Buy” and an average target price of $19.86.

Hims & Hers Health Stock Down 1.6 %

Shares of Hims & Hers Health stock opened at $16.30 on Tuesday. The firm has a market capitalization of $3.50 billion, a P/E ratio of -1,630.00 and a beta of 1.05. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74. The company has a 50 day moving average price of $17.71 and a 200 day moving average price of $17.03.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. During the same period in the previous year, the firm posted ($0.03) earnings per share. The business’s revenue for the quarter was up 51.8% compared to the same quarter last year. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, CEO Andrew Dudum sold 45,755 shares of the stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $22.97, for a total value of $1,050,992.35. Following the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $769,540.94. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Andrew Dudum sold 45,755 shares of the business’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $22.97, for a total value of $1,050,992.35. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $769,540.94. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Christiane Pendarvis sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total value of $106,050.00. Following the sale, the director now directly owns 23,917 shares in the company, valued at $362,342.55. The disclosure for this sale can be found here. Insiders sold a total of 752,820 shares of company stock worth $13,545,954 over the last three months. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.